1. 1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician's choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. (18th September 2019) Authors: Grisham, R; Monk J, B; Banerjee, S; Coleman L, R; Oza M, A; Oehler K, M; Kalbacher, E; Mirza Raza, M; del Campo M, J; Marth, C; Westermann, A; Pignata, S; Colombo, N; Cibula, D; Hilpert, F; Aghajanian, C; Drill, E; Sandor, V; Boyd P, A; Vergote, I Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗